Telix (TLX) | Stock Overview & Key Data
Telix Performance Comparison
Stock Range
Today's Range
Low: $12.90
High: $13.19
on August 1, 2025
52 Week Range
Low: $12.90
High: $30.36
on August 1, 2025
on February 24, 2025
All-Time High: $30.36 on February 24, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$4.4B
EPS
0.09
P/E Ratio (TTM)
145.00
Forward P/E
12.69
P/B Ratio
7.69
PEG Ratio
N/A
Div. Yield
N/A
ROE
13.92%
Beta
2.390
Debt to Equity
102.33
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
8.46%
Profit Margin
6.37%
Returns and Earnings
Return on Assets (TTM)
5.33%
Return on Equity (TTM)
13.92%
EBITDA
$92.3M
Net Income (TTM)
$32.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$1.51
Quarterly Revenue Growth (YoY)
48.80%
Quarterly Earnings Growth (YoY)
3.80%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Telix TLX | 4.37B Mid-cap | -8.10% | -18.84% | -27.26% | -28.92% | -13.00% | -12.12% | -12.12% | -12.12% |
| Vertex VRTX | 118.67B Large-cap | -1.60% | 2.20% | -7.36% | -1.75% | 13.89% | -6.54% | 60.45% | 69.28% |
| Regeneron REGN | 58.89B Large-cap | -0.75% | 4.48% | -5.28% | -16.19% | -21.86% | -48.36% | -8.92% | -9.89% |
| BridgeBio Pharma BBIO | 8.99B Mid-cap | 2.31% | 10.73% | 23.36% | 52.66% | 67.98% | 80.94% | 323.32% | 66.91% |
| Blueprint Medicines BPMC | 8.37B Mid-cap | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% | 12.60% | 149.54% | 73.38% |
| Bio-Techne TECH | 7.92B Mid-cap | -6.62% | 5.40% | 10.60% | -23.82% | -23.21% | -31.53% | -42.67% | -17.38% |
Ownership & Short Interest
Insider Ownership
0.00%
Institutional Ownership
0.04%
Shares Short
17K
Short Ratio
0.33
Short % of Shares Outstanding
0.01%
Average 10-Day Volume
84K
Average 90-Day Volume
63K
Telix Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Telix would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is TLX's 52-week high and low?
- In the last 52 weeks, Telix reached a high of $30.36 (on February 24, 2025) and a low of $12.90 (on August 1, 2025).
- What is the market cap and P/E ratio for TLX?
- Curious about Telix's size and valuation? Its market capitalization stands at 4.37B. When it comes to valuation, the P/E ratio (trailing twelve months) is 145.00, and the forward P/E (looking ahead) is 12.69.
- Does TLX pay dividends? If so, what's the yield?
- As for dividends, Telix isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Telix's main competitors or similar companies to consider before investing?
When looking at Telix, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX118.67B Healthcare Biotechnology -6.54% 60.45% Regeneron
REGN58.89B Healthcare Biotechnology -48.36% -8.92% BridgeBio Pharma
BBIO8.99B Healthcare Biotechnology 80.94% 323.32% Blueprint Medicines
BPMC8.37B Healthcare Biotechnology 12.60% 149.54% Bio-Techne
TECH7.92B Healthcare Biotechnology -31.53% -42.67% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Telix Pharmaceuticals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Telix's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 13.92%, the Debt to Equity ratio from the most recent quarter is 102.33, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for TLX?
- Looking at Telix's growth, its revenue over the trailing twelve months (TTM) was $507M. Compared to the same quarter last year (YoY), quarterly revenue grew by 48.80%, and quarterly earnings saw a YoY growth of 3.80%.
- How much of TLX stock is held by insiders and institutions?
- Wondering who owns Telix stock? Company insiders (like executives and directors) hold about 0.00% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.04%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.